Research-First Biotech
Programmable Neurobiology for Cognitive Health
Operating in stealth, with selective partnering and confidentiality.
Guided by careful science and responsibility in brain-related research.
Pioneering the Future of Cognitive Health
Manhattan Neuroscience is a research-driven biotechnology company exploring new approaches to brain health, bringing together a world-class team and selective partnerships to unlock new frontiers in neuroscience, computation, and biological understanding.
Our Approach
Computational Discovery
AI-guided hypothesis generation for multi-target biology.
Experimental Validation
Human-relevant models, multi-omics readouts, and rigorous replication.
Translation Path
Partnership, regulatory-minded development, and clear milestones.
Our Primary Research Domains
We apply our research framework across a small number of preclinical focus areas where regulatory biology and computation intersect.
Gene Regulation & Programmable Neurobiology
Neurodegeneration & Cognitive Aging (Preclinical)
Precision Neuropsychiatry (Preclinical)
AI-Driven Drug Discovery & Experimental Loops
Meet Our Advisors
-

George Church, PhD
Professor of Genetics at Harvard Medical School, and Founding Core Faculty Member of the Wyss Institute for Biologically Inspired Engineering.
-

Glenn Cohen, JD
Deputy Dean at Harvard Law School, James A. Attwood and Leslie Williams Professor of Law, and Faculty Director of the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics.
-

Jerrold Rosenbaum, MD
Stanley Cobb Professor of Psychiatry at Harvard Medical School, and Emeritus Chair of Psychiatry at Massachusetts General Hospital.
-

Maurizio Fava, MD
Psychiatrist-in-Chief at Massachusetts General Hospital; Chair of Psychiatry for Mass General Brigham Academic Medical Centers.
-

Stephen Haggarty, PhD
Director of the MGH Chemical Neurobiology Laboratory, Professor of Neurology at Harvard Medical School, and Senior Associate at the Broad Institute of Harvard/MIT.
-

Jacob Hooker, PhD
Lurie Family Professor of Radiology at Harvard Medical School and Director of Radiochemistry at Massachusetts General Hospital.
-

Brendan Hussey, PhD
President and CEO of Zymgeist Labs, Vice President at JLS Fund, former Associate at Stifel Investment Banking, with a background in Synthetic Biology from the University of Toronto.
-

Dominique Russo, MBA, MPA
Founder of Stealth in Silicon Valley and the Gulf Cooperation Council, Vice-Chair of the IEEE Group on Extended Reality (XR), and advisor guiding national leaders in innovation and AI-powered national strategy.
-

John Granata, MEng
Product Director at Coinbase, former Director of Engineering at Coinbase, with a background in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.
-

Logan Fahrenkopf, JD
Associate at Wilson Sonsini Goodrich & Rosati, with experience at Regeneron Pharmaceuticals and involvement in multiple Harvard Law initiatives, including the Intellectual Property Law Association, the Entrepreneur Project, and the Journal of Law and Technology.
-

Lily O’Brien, LLM
Law studies at the University of Oxford, Academic Scholar at Christ Church, graduate of The University of Law, with additional studies at Panthéon-Assas University and a Certificate Supérieur de Droit Français et International.
-

Amie Leighton, BA
Co-Founder of Allia Health, focused on Precision Psychiatry, with studies at the University of Oxford and Christ Church.
-

Ben Cyrulnik, MS
Investment Associate at JLS Fund, Patent Analyst at Calyx Law, with a background in Pharmaceutical Science from the University of Wisconsin–Madison.
-

Nick Castoria, MBA 2026
Harvard Business School, Strategy Consultant at Accenture, University of Pennsylvania Class of 2019, and participant in Sponsors for Educational Opportunity (SEO).
Our
Talent
Invitation
We’re assembling a small, exceptional team at the intersection of AI, genomics, and experimental biology. If you want to build rigorous, human-relevant neuroscience biotech—while protecting IP and moving fast with scientific discipline—we’d love to hear from you.
Who We’re Looking For
AI Drug Discovery
Foundation models for biology/chemistry, active learning, evals, and scientific software.
Gene Regulation / TF Biology
Gene regulatory networks, perturbation biology, and CRISPR screens—wet or dry.
Genomics and Multi-omics
Single-cell, epigenomics, causal inference, and integrative analysis.
Translational Experimentalists
Human cell models, assay development, and reproducibility-first workflows.
Operator-Builders
Platform engineering, data infrastructure, and lab automation interfaces.
Start a Conversation
Manhattan Neuroscience is assembling a world-class team and establishing strategic partnerships to advance the frontiers of neuroscience. Whether you are an investor, funder, or potential research collaborator, we invite you to connect with us via the form below. We will review all messages carefully and respond selectively.